|Bid||231.23 x 1000|
|Ask||271.30 x 800|
|Day's range||268.35 - 272.93|
|52-week range||165.52 - 272.93|
|Beta (5Y monthly)||1.40|
|PE ratio (TTM)||69.28|
|Earnings date||08 Feb 2022 - 14 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||300.22|
RESEARCH TRIANGLE PARK, N.C., December 09, 2021--Global spending on medicines — based on invoice price levels — is expected to grow at 3-6% CAGR through 2026 to reach about $1.8 trillion by 2026, including spending on COVID-19 vaccines and novel therapeutics, according to a new report, The Global Spending and Usage of Medicines, released by the IQVIA™ Institute for Human Data Science.
MENLO PARK, Calif. and SINGAPORE, Dec. 06, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of IQVIA Biotech, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, as its preferred clinical research organization for logistics related to decent
DocuSign's (DOCU) third-quarter fiscal 2022 earnings and revenues increase year over year.